Adrenocortical Carcinoma clinical trials at UCSD
1 research study open to eligible people
Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors
open to eligible people ages 18 years and up
This research study is studying a combination of drugs as a possible treatment for rare genitourinary malignancies. -The names of the study drugs involved in this study are: - Nivolumab - Ipilimumab
La Jolla, California and other locations
Last updated: